Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

J Dermatolog Treat. 2024 Dec;35(1):2375102. doi: 10.1080/09546634.2024.2375102. Epub 2024 Jul 4.

Authors

Luigi Gargiulo^{1

2}, Luciano Ibba^{1

2}, Matteo Bianco^{1

2}, Sara Di Giulio^{1

2}, Alfano Alfano^{1

2}, Ruggero Cascio Ingurgio^{1

2}, Paola Facheris¹, Chiara Perugini¹, Mario Valenti^{1

2}, Antonio Costanzo^{1

2}, Alessandra Narcisi¹

Affiliations

¹ Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.

PMID: 38964753
DOI: 10.1080/09546634.2024.2375102

No abstract available

Publication types

Letter

MeSH terms

Adult
Dermatitis, Atopic* / drug therapy
Dermatologic Agents / administration & dosage
Dermatologic Agents / therapeutic use
Female
Heterocyclic Compounds, 3-Ring* / administration & dosage
Heterocyclic Compounds, 3-Ring* / therapeutic use
Humans
Male
Middle Aged
Severity of Illness Index*
Treatment Outcome

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring
Dermatologic Agents